CLDF Title
Contact Us | Bookmark
  HBV   HCC   HCV   HE   NASH   PBC   OTHER
About CLDF Centers of Educational Expertise  
Live CME Meetings Webcasts Slide Library Abstract Library Conference Highlights
Featured Programs
      IC-Hep
 
             
  Liver News - REUTERS   Congress Calendar   Physician Resources  
 
 
Gilead wins reversal of $2.54 bln hepatitis C drug patent verdict
02-19-2018
One in 10 adults meet criteria for functional dyspepsia
02-09-2018
Special Report: U.S. body brokers supply world with torsos, limbs and heads
02-08-2018
People on liver transplant waitlist may be no worse off if they have used marijuana
02-08-2018
U.S. FDA approves Gilead's Biktarvy triple HIV drug
02-07-2018
View Complete News Library
 
 
March 10-14
AATOD - American Association for the Treatment of Opioid Dependence
New York, NY, USA
March 14-18
APASL - Asian Pacific Association for the Study of Liver
New Delhi, Delhi, India
March 24-25
GALA - GI & Liver Association of the Americas
Dallas, TX, USA
April 11-15
EASL - European Association for the Study of the Liver
Paris, France
April 12-15
ASAM - American Society of Addiction Medicine
San Diego, CA, USA
View all Congresses
 
 
 
 
 
 
 
  Line  
  Featured Abstracts          
 
Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis
 
Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)
 
An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis
 
Hepatocellular carcinoma
 
Patterns of Discordance Between Pretransplant Imaging Stage of Hepatocellular Carcinoma and Posttransplant Pathologic Stage: A Contemporary Appraisal of the Milan Criteria
 
 
Laparoscopic liver resection for hepatocellular carcinoma in early and advanced cirrhosis
 
Hepatitis C eradication with DAA and risk of liver cancer recurrence: the debate unrests
 
Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group
 
Influence of birth origin and risk factor profile on hepatitis B mortality: Philadelphia, PA 2003-2013
 
Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic Impairment
 
 
GHOST: global hepatitis outbreak and surveillance technology
 
HCV clearance by direct-acting antiviral treatments reverses insulin resistance in chronic hepatitis C patients
 
Hepatitis C virus infection and development of type 2 diabetes mellitus: Systematic review and meta-analysis of the literature
 
Clinical epidemiology and disease burden of nonalcoholic fatty liver disease
 
 
          View All Abstracts  
  Line  
                               
 
HBV
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
 
HE
Webcasts
Slide Library
Abstract Library
 
NASH
Webcasts
Slide Library
Abstract Library
 
 
PBC
Webcasts
Slide Library
Abstract Library
 
 
OTHER
Webcasts
Slide Library
   
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Sponsors & Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Hepatology
Substance Use Disorder
             
CLDF Follow Us
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2018 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.